Company profile for Allarity Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Allarity Therapeutics is a late clinical-stage, precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Allarity’s clinical program includes six anti-cancer assets in mid- to late-stage clinical development. Our programs and partnerships leverage our proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient sel...
Allarity Therapeutics is a late clinical-stage, precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Allarity’s clinical program includes six anti-cancer assets in mid- to late-stage clinical development. Our programs and partnerships leverage our proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Our DRP® technology has been broadly validated across an extensive array of therapies & tumor types with a high degree of accuracy for matching the right patient to the right drug.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Denmark
Address
Address
Venlighedsvej 1 2970 Horsholm
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/14/3188337/0/en/Allarity-Therapeutics-Provides-Third-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html

GLOBENEWSWIRE
14 Nov 2025

https://www.globenewswire.com/news-release/2025/09/22/3153846/0/en/Allarity-Therapeutics-Presents-New-Phase-2-Clinical-Data-for-Stenoparib-2X-121-Showing-Landmark-Median-Overall-Survival-Has-Now-Surpassed-25-Months.html

GLOBENEWSWIRE
22 Sep 2025

https://www.globenewswire.com/news-release/2025/09/17/3151554/0/en/Allarity-Therapeutics-CEO-to-Present-at-Biomarkers-Precision-Medicine-2025.html

GLOBENEWSWIRE
17 Sep 2025

https://www.globenewswire.com/news-release/2025/08/26/3139198/0/en/Allarity-Therapeutics-Granted-FDA-Fast-Track-Designation-for-Stenoparib-for-the-Treatment-of-Advanced-Ovarian-Cancer.html

GLOBENEWSWIRE
26 Aug 2025

https://www.globenewswire.com/news-release/2025/08/15/3134474/0/en/Allarity-Therapeutics-Provides-Second-Quarter-2025-Update-Highlighting-Clinical-Progress-IP-Expansion-and-New-Partnerships.html

GLOBENEWSWIRE
15 Aug 2025

https://www.globenewswire.com/news-release/2025/07/15/3115497/0/en/Allarity-Therapeutics-Announces-New-Licensing-and-Laboratory-Services-Agreement-to-Expand-DRP-Platform-Utilization.html

GLOBENEWSWIRE
15 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty